Similar outcomes in Asian and Western patients with diffuse large B-cell lymphoma treated with R-CHOP

Leukemia Research

Volumn 37, Issue 4, 2013, Pages 386-391

  Castillo, Jorge J ^a   Sinclair, Natalie ^a   Beltrán, Brady E ^b   Song, Moo Kon ^c   Ilic, Ivana ^d   Leppa, Sirpa ^e   Nurmi, Heidi ^e   Seki, Ritsuko ^f   Uccella, Silvia ^g   Li, Jun Min ^h   Treaba, Diana O ^a   Stachurski, Dariusz ^a   Butera, James N ^a  

^a RHODE ISLAND HOSPITAL   (United States)

^b HOSPITAL NACIONAL EDGARDO REBAGLIATI MARTINS   (Peru)

^c Pusan National University School of Medicine   (South Korea)

^d KBC Zagreb   (Croatia)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g UNIVERSITY OF INSUBRIA   (Italy)

^h SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

Chemoimmunotherapy; DLBCL; R CHOP; Race; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; LACTATE DEHYDROGENASE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGE; AGED; ARTICLE; ASIAN; CANCER PROGNOSIS; CANCER STAGING; CAUCASIAN; FEMALE; FOLLOW UP; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RACE DIFFERENCE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIA; CYCLOPHOSPHAMIDE; DOXORUBICIN; EUROPE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; PREDNISONE; PROGNOSIS; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 84875376676     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.01.002     Document Type: Article

References (29)

1. Stein H., Warnke R., Chan W., et al. Diffuse large B-cell lymphoma, not otherwise specified. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, 233-237. IARC, Lyon, France. S. Swerdlow (Ed.).
2. Feugier P., Van Hoof A., Sebban C., et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005, 23:4117-4126.
3. Pfreundschuh M., Trumper L., Osterborg A., et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006, 7:379-391.
4. Habermann T.M., Weller E.A., Morrison V.A., et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006, 24:3121-3127.
5. Lenz G., Wright G., Dave S.S., et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008, 359:2313-2323.
6. Alizadeh A.A., Eisen M.B., Davis R.E., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
7. Rosenwald A., Wright G., Chan W.C., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:1937-1947.
8. Ke X., Wang J., Gao Z., et al. Clinical characteristics and prognostic analysis of Chinese patients with diffuse large B-cell lymphoma. Blood Cells Mol Dis 2010, 44:55-61.
9. Shia A.K., Gan G.G., Jairaman S., et al. High frequency of germinal centre derivation in diffuse large B cell lymphoma from Asian patients. J Clin Pathol 2005, 58:962-967.
10. Shiozawa E., Yamochi-Onizuka T., Takimoto M., et al. The GCB subtype of diffuse large B-cell lymphoma is less frequent in Asian countries. Leuk Res 2007, 31:1579-1583.
11. Ilic I., Mitrovic Z., Aurer I., et al. Lack of prognostic significance of the germinal-center phenotype in diffuse large B-cell lymphoma patients treated with CHOP-like chemotherapy with and without rituximab. Int J Hematol 2009, 90:74-80.
12. Nyman H., Adde M., Karjalainen-Lindsberg M.L., et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007, 109:4930-4935.
13. Seki R., Ohshima K., Fujisaki T., et al. Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era. Cancer Sci 2009, 100:1842-1847.
14. Song M.K., Chung J.S., Seol Y.M., et al. Influence of low absolute lymphocyte count of patients with nongerminal center type diffuse large B-cell lymphoma with R-CHOP therapy. Ann Oncol 2010, 21:140-144.
15. Uccella S., Placidi C., Marchet S., et al. Bcl-6 protein expression, and not the germinal centre immunophenotype, predicts favourable prognosis in a series of primary nodal diffuse large B-cell lymphomas: a single centre experience. Leuk Lymphoma 2008, 49:1321-1328.
16. Xia Z.G., Xu Z.Z., Zhao W.L., et al. The prognostic value of immunohistochemical subtyping in Chinese patients with de novo diffuse large B-cell lymphoma undergoing CHOP or R-CHOP treatment. Ann Hematol 2010, 89:171-177.
17. Castillo J.J., Beltran B.E., Song M.K., et al. The Hans algorithm is not prognostic in patients with diffuse large B-cell lymphoma treated with R-CHOP. Leuk Res 2012, 36:413-417.
18. Hans C.P., Weisenburger D.D., Greiner T.C., et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004, 103:275-282.
19. Carreon J.D., Morton L.M., Devesa S.S., et al. Incidence of lymphoid neoplasms by subtype among six Asian ethnic groups in the United States, 1996-2004. Cancer Causes Control 2008, 19:1171-1181.
20. Griffiths R., Gleeson M., Knopf K., et al. Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL). BMC Cancer 2010, 10:625.
21. Komrokji R.S., Al Ali N.H., Beg M.S., et al. Outcome of diffuse large B-Cell lymphoma in the United States has improved over time but racial disparities remain: review of SEER data. Clin Lymphoma Myeloma Leuk 2011, 11:257-260.
22. Shenoy P.J., Malik N., Nooka A., et al. Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma n the United States. Cancer 2010.
23. Wu X.C., Andrews P., Chen V.W., et al. Incidence of extranodal non-Hodgkin lymphomas among whites, blacks, and Asians/Pacific Islanders in the United States: anatomic site and histology differences. Cancer Epidemiol 2009, 33:337-346.
24. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993, 329:987-994.
25. Ziepert M., Hasenclever D., Kuhnt E., et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+B-cell lymphoma in the rituximab era. J Clin Oncol 2010, 28:2373-2380.
26. Chen Y., Chen H., Fu K., et al. Prevalence of germinal center B-cell-like and non-germinal center B-cell-like types of diffuse large B-cell lymphoma in Shanghai, China. Zhonghua Bing Li Xue Za Zhi 2010, 39:313-318.
27. Li T., Medeiros L.J., Lin P., et al. Immunohistochemical profile and fluorescence in situ hybridization analysis of diffuse large B-cell lymphoma in northern China. Arch Pathol Lab Med 2010, 134:759-765.
28. de Jong D., Rosenwald A., Chhanabhai M., et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications-a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 2007, 25:805-812.
29. Meyer P.N., Fu K., Greiner T.C., et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 2011, 29:200-207.